Tyrosine Kinase Inhibitors
Results of the ENESTop study demonstrate the potential for patients with CML who had deep molecular response to achieve long-term treatment-free remission (TFR) after second-line nilotinib, increasing the focus of TFR as a therapeutic outcome.
Nonrandomized trial demonstrates tolerability and antitumor activity of a PD-1 checkpoint inhibitor plus a VEGF-TKI in patients with treatment-naïve advanced RCC.
Phase 3 study sought to assess the associations between adjuvant therapy with VEGF-tyrosine kinase inhibitors (TKIs) and benefit, sex, and age in patients with resected renal cell cancer.
Researchers evaluated the effect of antibiotics on treatment delays, interruptions, and dose reductions in patients with mRCC treated with a first-line VEGF-TKI and presented their results at the 2018 Genitourinary Cancers Symposium.
Although TKIs improve outcomes, they are still associated with toxicities common with cancer therapies, such as fatigue.
Results of a double-blind phase 2 study determined if adding oral pazopanib to intravenous paclitaxel improved outcomes for women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
Ibrutinib — a Bruton tyrosine kinase inhibitor — is currently used among patients with WM who have previously received treatment. This prospective, phase 2 study sought to determine its efficacy as a first-line therapy in treatment-naive patients.
Acalabrutinib is a treatment option for patients with mantle cell lymphoma who have not responded to prior treatment.
Osimertinib in the Treatment of Non-small Cell Lung Cancer: Design, Development and Place in TherapyOctober 13, 2017
[Lung cancer: Targets and Therapy] This research examines clinical data from Phase I-III trials of osimertinib, discusses mechanisms of resistance to osimertinib, and provides an outlook for the use of osimertinib and novel therapeutic combinations to improve EGFR-mutated NSCLC outcomes.
Treatment options for brain metastases in patients with EGFR-mutant NSCLC include SRS, WBRT, and EGFR TKIs. In this study, researchers sought to determine the optimal treatment approach of those who develop brain metastases and have not received EFGR TKIs.
Ceritinib is a kinase inhibitor indicated for the treatment of patients with ALK-positive metastatic NSCLC who have progressed on or are intolerant to crizotinib; in this study, researchers determined the efficacy of ceritinib in patients with untreated ALK-rearranged NSCLC.
A review of adverse effects and recommended management for 3 kinase inhibitors indicated for the treatment of gastrointestinal cancers.
Patients with chronic lymphocytic leukemia (CLL) who discontinue TKI therapy due to toxicity can successfully be treated with an alternate TKI.
The addition of vandetanib to a platinum agent and etoposide did not improve time to progression or overall survival in patients with newly diagnosed extensive-stage SCLC.
Patients with medullary thyroid cancer who harbor RET M918T or RAS mutations may derive greater clinical benefit from cabozantinib compared with patients who do not have those genetic mutations.
Patients with metastatic non-small cell lung cancer demonstrated prolonged median progression-free survival with the administration of erlotinib below the maximum tolerated dose.
Presence of certain microRNAs (miRNAs) is predictive of response to TKIs and prognosis for patients with metastatic renal cell carcinoma (mRCC).
For patients with chronic myeloid leukemia treated with lifelong targeted therapies, social support is crucial for maintaining psychological well-being.
Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) plus ponatinib appears to be superior to hyper-CVAD plus dasatinib for the frontline treatment of patients with Philadelphia chromosome-positive ALL.
Cobimetinib in combination with vemurafenib as a standard first-line approach improves survival in patients with BRAF V600 mutation-positive melanoma, updated results of the coBRIM study.
Tyrosine Kinase Inhibitor Therapy Can Be Safely Stopped in Select Patients With CML in Chronic PhaseJuly 29, 2016
A high percentage of patients with CML treated with TKIs achieve deep molecular responses and can safely stop therapy. Initials results of the EURO-SKI trial define prognostic markers that indicate durability of deep molecular responses after stopping TKI therapy.
Scientists discovered the compound eCF506. This compound was more effective than existing medicines at targeting breast cancer cells because it more selectively inhibited SRC tyrosine kinase.
Treatment Compliance and Severe Adverse Events Limit the Use of Tyrosine Kinase Inhibitors in Refractory Thyroid CancerOctober 29, 2015
[OncoTargets and Therapy] This research examines patient compliance with tyrosine kinase inhibitor (TKI) treatment for refractory and progressive thyroid cancer, as well as exploring the efficacy and serious adverse events associated with this treatment.
Increased risk of Severe Infections in Cancer Patients Treated With Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: A Meta-AnalysisSeptember 29, 2015
[OncoTargets and Therapy] This research examines the risks and benefits associated with using small-molecule vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs).
Afatinib is clinically active and well tolerated in many tyrosine kinase inhibitor (TKI)-pretreated patients with non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations, according to a new study.
A new tool predicts what genetics are truly driving the cancer in any population of cells and helps the user choose the best kinase inhibitor to address the issue.
[Breast Cancer: Targets and Therapy] This research reviews the preclinical as well as clinical data on neratinib.
What data are available concerning inter- and intrapatient variability in the pharmacokinetics of TKIs in chronic myeloid leukemia?
Improved tyrosine kinase inhibitor (TKI) selectively activates in tumor tissue, minimizing side effects in patientsOctober 24, 2014
A new strategy developed by an interdisciplinary team of researchers aims to reduce the side effects connected to use of tyrosine kinase inhibitors (TKIs).
IMPRESS trial fails to find benefit from more tyrosine kinase inhibitor (TKI) treatment after resistance developsOctober 17, 2014
Patients with lung cancer that have developed resistance to the drug gefitinib experience no statistically significant improvement in progression-free survival when continued use of the drug with chemotherapy is utilized.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- A Witness to Letting Go: Nursing Care at the End of Life
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Androgen-Deprivation Therapy for Prostate Cancer May Cause Nocturia, Sleep Disturbance
- USPSTF Rates Ovarian Cancer Screening a D for Asymptomatic, Low-Risk Women
- Colorectal Cancer Screening Rate Increased by Digital Self-Ordering
- Presence of Iris Pigmented Lesions Indicates Melanoma Risk
- A Witness to Letting Go: Nursing Care at the End of Life
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|